Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
A phase 3 trial of Cisplatin and Sodium thiosulfate in Hepatocellular carcinoma, run by University of Birmingham, completed.
Overview
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer is a phase 3 interventional study registered as NCT00652132 by University of Birmingham, with 116 participants recorded, started 2007-12-15 and reaching its primary completion in 2017-09-04. Interventions recorded: cisplatin, sodium thiosulfate. Conditions recorded: Liver Cancer, Ototoxicity.
Linked to the drug Sodium thiosulfate because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Shares Sodium thiosulfate (otoprotectant), Hepatocellular carcinoma and the tag pipeline.
- TrialA Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Shares Sodium thiosulfate (otoprotectant), Cisplatin and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialApplicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Shares Cisplatin, Hepatocellular carcinoma and the tag pipeline.
- TrialApplicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Shares Cisplatin, Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialThermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Shares Hepatocellular carcinoma and the tag pipeline.